Merck's Blockbuster Drug Wins Key New FDA Approval
One of the world's most successful drugs, Merck's (NYSE: MRK) Keytruda, stands to become even more prominent following an important new approval. The U.S. Food and Drug Administration (FDA) gave it the green light for the treatment of a particularly stubborn type of bladder cancer.
The FDA's approval covers high-risk, non-muscle-invasive bladder cancer that has not responded to the Bacillus Calmette-Guerin vaccine. The approval is not broad; it applies only to patients who have already received other forms of treatment, and cannot or are unwilling to have their bladders surgically removed.
Image source: Getty Images.
Source Fool.com
